ASX-listed ResMed slips after Jarden cuts PT
ASX-listed shares of medical devices manufacturer ResMed RMD.AX fall 1.2% to A$33.42
Jarden cuts price target to A$39.97 from A$41.48, maintains "overweight" rating on stock
New price target represents an upside of 18.2% to stock's last close
Brokerage forecasts RMD's third-quarter adjusted NPAT at $362.9 million, up 15.4% pcp, despite noting a slowdown in U.S. device sales
Expects RMD flipping to net cash position of around $66 million in third quarter, which could allow co to be more definitive with its buy-back strategy in future
Stock down 9.1% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Musk’s XChat Is Coming to App Store, Meta, Apple and Finance World Are Trembling

What is the CLARITY Act? 2026 Guide to US Crypto Regulation and Stablecoin Yield Rules

Anthropic IPO 2026: What the Claude Mythos Release Delay Means for Investors and Stock Valuation

Microsoft Launches Its Own AI Models and Ditches OpenAI Dependence - Is MSFT Stock a Buy at $370?

Anthropic Claude Mythos Preview Sparks Wall Street Panic: Bessent, Powell Summon CEOs; Cloudflare Tumbles 8%

Tradingkey






